Kathleen Gondek

Summary

Affiliation: Bayer HealthCare
Country: USA

Publications

  1. ncbi Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels
    Kathleen Gondek
    Bayer Corporation, West Haven, CT 06516, USA
    J Clin Oncol 25:5087-93. 2007
  2. ncbi The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners
    Dana Britt DiBenedetti
    Research Triangle Institute, NC, USA
    Eur Urol 48:503-11. 2005
  3. ncbi Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA)
    Diane J Wild
    Oxford Outcomes Ltd, Old Barn, Jericho Farm, Cassington, Oxford, OX29 4SZ, UK
    Health Qual Life Outcomes 3:42. 2005
  4. ncbi Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire
    Darren Clayson
    Oxford Outcomes Ltd, Oxford, UK
    BJU Int 96:350-9. 2005
  5. ncbi Responsiveness and minimum important differences for the erection quality scale
    Raymond C Rosen
    Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA
    J Urol 178:2076-81. 2007
  6. ncbi Patient-reported outcomes assessment in cancer trials: taking stock, moving forward
    Joseph Lipscomb
    Emory University, Atlanta, GA 30322, USA
    J Clin Oncol 25:5133-40. 2007
  7. ncbi Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
    David Cella
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    J Support Oncol 4:191-9. 2006
  8. ncbi Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer
    Ronald Bukowski
    CCF Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Am J Clin Oncol 30:220-7. 2007
  9. ncbi The identification of benefit in medical intervention: an overview and suggestions for process
    Paul E Stang
    Research and Development, Johnson and Johnson Pharmaceuticals, Titusville, NJ, USA
    Am J Ther 15:495-503. 2008

Collaborators

Detail Information

Publications9

  1. ncbi Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels
    Kathleen Gondek
    Bayer Corporation, West Haven, CT 06516, USA
    J Clin Oncol 25:5087-93. 2007
    ..Collecting PRO data can enhance our understanding of cancer burden and the impact of interventions on patients' lives...
  2. ncbi The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners
    Dana Britt DiBenedetti
    Research Triangle Institute, NC, USA
    Eur Urol 48:503-11. 2005
    ..CONCLUSION: The TSS is brief, culturally valid, and the most comprehensive multidimensional measure of satisfaction with ED treatment for patients and their partners, and addresses some of the shortcomings of existing measures...
  3. ncbi Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA)
    Diane J Wild
    Oxford Outcomes Ltd, Old Barn, Jericho Farm, Cassington, Oxford, OX29 4SZ, UK
    Health Qual Life Outcomes 3:42. 2005
    ..To validate a questionnaire to assess the activity impairment associated with uncomplicated urinary tract infection (uUTI)...
  4. ncbi Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire
    Darren Clayson
    Oxford Outcomes Ltd, Oxford, UK
    BJU Int 96:350-9. 2005
    ..CONCLUSION: The three-domain UTISA has excellent psychometric properties and it is likely to prove an excellent tool for assessing uUTI outcome from a patient's perspective, both in research and clinical settings...
  5. ncbi Responsiveness and minimum important differences for the erection quality scale
    Raymond C Rosen
    Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA
    J Urol 178:2076-81. 2007
    ..We evaluated the responsiveness and treatment sensitivity of the Erection Quality Scale, and provided further psychometric validation of this scale...
  6. ncbi Patient-reported outcomes assessment in cancer trials: taking stock, moving forward
    Joseph Lipscomb
    Emory University, Atlanta, GA 30322, USA
    J Clin Oncol 25:5133-40. 2007
    ....
  7. ncbi Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
    David Cella
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    J Support Oncol 4:191-9. 2006
    ..Thus, the FKSI-15 and FKSI-10 are reliable and valid symptom indices for evaluating kidney cancer patients...
  8. ncbi Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer
    Ronald Bukowski
    CCF Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Am J Clin Oncol 30:220-7. 2007
    ..The aim of the current study was to determine the impact of treatment with sorafenib versus placebo on renal cancer symptoms and quality of life (QOL)...
  9. ncbi The identification of benefit in medical intervention: an overview and suggestions for process
    Paul E Stang
    Research and Development, Johnson and Johnson Pharmaceuticals, Titusville, NJ, USA
    Am J Ther 15:495-503. 2008
    ..As the emphasis is on transparency, relevance, applicability, and communication, this approach to assessing benefit should maximize the impact of these data to all stakeholders and decision makers...